Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Sinusitis | 55 | 2023 | 210 | 8.100 |
Why?
|
Rhinitis | 44 | 2023 | 175 | 6.770 |
Why?
|
Rhinitis, Allergic, Seasonal | 43 | 2017 | 179 | 5.630 |
Why?
|
Rhinitis, Allergic, Perennial | 24 | 2023 | 81 | 3.640 |
Why?
|
Tonsillectomy | 8 | 2023 | 30 | 3.640 |
Why?
|
Nasal Polyps | 18 | 2023 | 58 | 3.500 |
Why?
|
Nasal Mucosa | 44 | 2016 | 186 | 2.900 |
Why?
|
Rhinitis, Allergic | 11 | 2024 | 43 | 2.830 |
Why?
|
Nasal Provocation Tests | 36 | 2023 | 129 | 2.700 |
Why?
|
Hypersensitivity | 19 | 2024 | 154 | 2.640 |
Why?
|
Sleep Apnea, Obstructive | 8 | 2023 | 219 | 2.500 |
Why?
|
Allergens | 30 | 2024 | 179 | 2.360 |
Why?
|
Adenoidectomy | 9 | 2023 | 23 | 2.150 |
Why?
|
Androstadienes | 9 | 2013 | 72 | 2.100 |
Why?
|
Nose | 11 | 2022 | 94 | 1.790 |
Why?
|
Anti-Allergic Agents | 13 | 2015 | 39 | 1.780 |
Why?
|
Sleep Apnea, Central | 2 | 2022 | 14 | 1.650 |
Why?
|
Paranasal Sinuses | 13 | 2021 | 60 | 1.460 |
Why?
|
Eosinophils | 18 | 2013 | 194 | 1.430 |
Why?
|
Anti-Inflammatory Agents | 12 | 2016 | 339 | 1.300 |
Why?
|
Maxillary Sinusitis | 4 | 2015 | 16 | 1.290 |
Why?
|
Humans | 192 | 2024 | 86678 | 1.220 |
Why?
|
Otolaryngology | 4 | 2023 | 53 | 1.190 |
Why?
|
Acetates | 5 | 2010 | 66 | 1.180 |
Why?
|
Eye | 4 | 2013 | 111 | 1.130 |
Why?
|
Quinolines | 5 | 2010 | 95 | 1.120 |
Why?
|
Chronic Disease | 30 | 2023 | 973 | 1.100 |
Why?
|
Endoscopy | 13 | 2022 | 332 | 1.090 |
Why?
|
Nasal Cavity | 15 | 2014 | 91 | 1.080 |
Why?
|
Administration, Intranasal | 26 | 2020 | 136 | 1.060 |
Why?
|
Leukotriene Antagonists | 7 | 2015 | 25 | 1.050 |
Why?
|
Sleep Apnea Syndromes | 3 | 2022 | 103 | 0.980 |
Why?
|
Double-Blind Method | 35 | 2016 | 1824 | 0.970 |
Why?
|
Glucocorticoids | 6 | 2015 | 352 | 0.960 |
Why?
|
Male | 105 | 2023 | 40988 | 0.960 |
Why?
|
Tracheotomy | 4 | 2020 | 18 | 0.940 |
Why?
|
Loratadine | 7 | 2008 | 21 | 0.940 |
Why?
|
Adrenal Cortex Hormones | 10 | 2023 | 263 | 0.920 |
Why?
|
Histamine | 11 | 2013 | 126 | 0.910 |
Why?
|
Ganglioneuroblastoma | 1 | 2023 | 4 | 0.900 |
Why?
|
Female | 106 | 2023 | 44550 | 0.900 |
Why?
|
Histamine H1 Antagonists | 7 | 2002 | 40 | 0.860 |
Why?
|
Cross-Over Studies | 23 | 2016 | 399 | 0.850 |
Why?
|
Child, Preschool | 23 | 2023 | 3613 | 0.830 |
Why?
|
Adult | 84 | 2021 | 25659 | 0.820 |
Why?
|
Ambrosia | 5 | 2012 | 14 | 0.800 |
Why?
|
Asthma | 13 | 2024 | 955 | 0.790 |
Why?
|
Terfenadine | 8 | 2004 | 22 | 0.770 |
Why?
|
Polysomnography | 7 | 2019 | 151 | 0.710 |
Why?
|
Quality of Life | 23 | 2023 | 1585 | 0.690 |
Why?
|
Child | 32 | 2021 | 6928 | 0.690 |
Why?
|
Histamine Release | 9 | 2008 | 53 | 0.680 |
Why?
|
Mouth Diseases | 1 | 2018 | 15 | 0.660 |
Why?
|
Immunoglobulin E | 11 | 2018 | 144 | 0.660 |
Why?
|
Budesonide | 4 | 2014 | 45 | 0.650 |
Why?
|
Maxillary Sinus | 3 | 2013 | 26 | 0.640 |
Why?
|
Humidity | 15 | 2008 | 89 | 0.640 |
Why?
|
Choristoma | 1 | 2018 | 68 | 0.640 |
Why?
|
Stomach | 1 | 2018 | 108 | 0.620 |
Why?
|
Cysts | 1 | 2018 | 104 | 0.610 |
Why?
|
Air | 8 | 2008 | 62 | 0.580 |
Why?
|
Sneezing | 10 | 2011 | 36 | 0.580 |
Why?
|
Methyl Ethers | 2 | 2013 | 33 | 0.570 |
Why?
|
Anesthesia, Inhalation | 2 | 2013 | 36 | 0.570 |
Why?
|
Anesthesia, Intravenous | 2 | 2013 | 35 | 0.570 |
Why?
|
Methacholine Chloride | 10 | 2002 | 64 | 0.560 |
Why?
|
Propofol | 2 | 2013 | 89 | 0.550 |
Why?
|
Blood Loss, Surgical | 2 | 2013 | 112 | 0.550 |
Why?
|
Headache | 2 | 2015 | 73 | 0.540 |
Why?
|
Nasal Decongestants | 4 | 2018 | 10 | 0.520 |
Why?
|
Ephedrine | 2 | 2006 | 6 | 0.520 |
Why?
|
Intestines | 1 | 2018 | 411 | 0.510 |
Why?
|
Nasal Lavage Fluid | 10 | 2012 | 26 | 0.510 |
Why?
|
Paranasal Sinus Diseases | 3 | 2013 | 25 | 0.500 |
Why?
|
Treatment Outcome | 21 | 2022 | 7998 | 0.500 |
Why?
|
Device Removal | 1 | 2015 | 161 | 0.480 |
Why?
|
Personnel Selection | 1 | 2014 | 59 | 0.470 |
Why?
|
Anaphylaxis | 2 | 2024 | 33 | 0.470 |
Why?
|
Osteogenesis, Distraction | 3 | 2020 | 24 | 0.470 |
Why?
|
Airway Obstruction | 4 | 2020 | 109 | 0.470 |
Why?
|
Mycoses | 2 | 2014 | 46 | 0.470 |
Why?
|
Nasal Obstruction | 4 | 2023 | 21 | 0.470 |
Why?
|
Reflex | 8 | 2013 | 79 | 0.470 |
Why?
|
Middle Aged | 43 | 2017 | 25040 | 0.470 |
Why?
|
Eosinophilia | 4 | 2017 | 84 | 0.460 |
Why?
|
Beclomethasone | 5 | 1998 | 16 | 0.460 |
Why?
|
Clinical Decision-Making | 1 | 2015 | 257 | 0.460 |
Why?
|
Eye Diseases | 2 | 2011 | 53 | 0.460 |
Why?
|
Internship and Residency | 3 | 2023 | 1010 | 0.460 |
Why?
|
Dibenzoxepins | 1 | 2013 | 5 | 0.450 |
Why?
|
Oxymetazoline | 3 | 2011 | 10 | 0.440 |
Why?
|
Education, Medical, Graduate | 2 | 2014 | 373 | 0.430 |
Why?
|
Mucociliary Clearance | 3 | 2007 | 7 | 0.430 |
Why?
|
Adolescent | 27 | 2016 | 8984 | 0.420 |
Why?
|
Desensitization, Immunologic | 7 | 2024 | 36 | 0.420 |
Why?
|
Abscess | 2 | 2015 | 91 | 0.410 |
Why?
|
Atropine | 5 | 1996 | 59 | 0.410 |
Why?
|
Adenoids | 1 | 2011 | 9 | 0.410 |
Why?
|
Mandible | 4 | 2020 | 119 | 0.400 |
Why?
|
Ear Diseases | 1 | 2011 | 19 | 0.390 |
Why?
|
Vitamin D | 2 | 2010 | 261 | 0.380 |
Why?
|
Interleukins | 1 | 2011 | 134 | 0.380 |
Why?
|
Postoperative Complications | 5 | 2019 | 2207 | 0.380 |
Why?
|
Gastroesophageal Reflux | 2 | 2016 | 117 | 0.370 |
Why?
|
Histamine H1 Antagonists, Non-Sedating | 3 | 2008 | 13 | 0.370 |
Why?
|
Carbon Dioxide | 1 | 2011 | 188 | 0.370 |
Why?
|
Tomography, X-Ray Computed | 12 | 2018 | 2601 | 0.370 |
Why?
|
Steroids | 3 | 2022 | 177 | 0.360 |
Why?
|
Respiratory Tract Diseases | 2 | 2001 | 45 | 0.360 |
Why?
|
Reflex, Abnormal | 1 | 2009 | 5 | 0.350 |
Why?
|
Drug Therapy, Combination | 7 | 2018 | 895 | 0.350 |
Why?
|
Pierre Robin Syndrome | 2 | 2020 | 13 | 0.340 |
Why?
|
Severity of Illness Index | 8 | 2020 | 1802 | 0.340 |
Why?
|
Job Application | 1 | 2008 | 8 | 0.340 |
Why?
|
Pollen | 7 | 2011 | 80 | 0.330 |
Why?
|
Lung Diseases | 1 | 2011 | 263 | 0.330 |
Why?
|
Cytokines | 9 | 2022 | 778 | 0.330 |
Why?
|
Biological Products | 3 | 2020 | 143 | 0.330 |
Why?
|
Inhalation | 2 | 2010 | 31 | 0.320 |
Why?
|
Conjunctivitis, Allergic | 1 | 2008 | 10 | 0.320 |
Why?
|
Infant | 13 | 2021 | 3047 | 0.320 |
Why?
|
Cervical Plexus | 1 | 2007 | 4 | 0.320 |
Why?
|
Cranial Nerve Neoplasms | 1 | 2007 | 12 | 0.320 |
Why?
|
Esophageal Sphincter, Upper | 1 | 2007 | 5 | 0.320 |
Why?
|
Vagus Nerve | 1 | 2007 | 45 | 0.310 |
Why?
|
Staphylococcal Infections | 3 | 2008 | 255 | 0.310 |
Why?
|
Ipratropium | 5 | 2003 | 18 | 0.310 |
Why?
|
Neurilemmoma | 1 | 2007 | 34 | 0.310 |
Why?
|
Esophageal Diseases | 1 | 2007 | 26 | 0.310 |
Why?
|
Phthalazines | 3 | 2008 | 39 | 0.310 |
Why?
|
Pneumococcal Infections | 6 | 2008 | 46 | 0.310 |
Why?
|
Evidence-Based Medicine | 5 | 2019 | 429 | 0.300 |
Why?
|
Cyclopropanes | 5 | 2010 | 25 | 0.300 |
Why?
|
Papillomavirus Infections | 2 | 2021 | 239 | 0.300 |
Why?
|
Sulfides | 5 | 2010 | 68 | 0.290 |
Why?
|
Methicillin Resistance | 1 | 2006 | 32 | 0.290 |
Why?
|
Mast Cells | 4 | 2012 | 92 | 0.280 |
Why?
|
Adrenergic alpha-Agonists | 1 | 2006 | 34 | 0.280 |
Why?
|
Antigens | 7 | 2001 | 228 | 0.280 |
Why?
|
Retrospective Studies | 11 | 2021 | 8496 | 0.280 |
Why?
|
Deglutition | 1 | 2006 | 73 | 0.280 |
Why?
|
T-Lymphocytes, Regulatory | 3 | 2014 | 295 | 0.280 |
Why?
|
Comorbidity | 5 | 2016 | 944 | 0.270 |
Why?
|
Infant, Newborn | 8 | 2021 | 2379 | 0.270 |
Why?
|
Cell Adhesion Molecules | 3 | 1995 | 163 | 0.270 |
Why?
|
Practice Guidelines as Topic | 7 | 2020 | 1037 | 0.270 |
Why?
|
Tracheal Neoplasms | 1 | 2005 | 8 | 0.270 |
Why?
|
Papilloma | 1 | 2005 | 22 | 0.260 |
Why?
|
Hot Temperature | 7 | 2008 | 206 | 0.260 |
Why?
|
Consensus | 4 | 2023 | 336 | 0.260 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 316 | 0.250 |
Why?
|
Coronavirus Infections | 2 | 2020 | 301 | 0.250 |
Why?
|
Acute Disease | 6 | 2020 | 826 | 0.250 |
Why?
|
Laryngeal Neoplasms | 1 | 2005 | 89 | 0.250 |
Why?
|
Statistics, Nonparametric | 6 | 2019 | 308 | 0.240 |
Why?
|
Patient Selection | 3 | 2020 | 686 | 0.240 |
Why?
|
Prospective Studies | 11 | 2021 | 4214 | 0.230 |
Why?
|
Parotitis | 1 | 2003 | 6 | 0.230 |
Why?
|
Staphylococcus aureus | 1 | 2006 | 263 | 0.230 |
Why?
|
Temperature | 5 | 2007 | 396 | 0.230 |
Why?
|
Surveys and Questionnaires | 9 | 2016 | 2504 | 0.230 |
Why?
|
Iron-Dextran Complex | 1 | 2023 | 1 | 0.230 |
Why?
|
Bacterial Infections | 2 | 2014 | 182 | 0.230 |
Why?
|
Women | 1 | 2023 | 25 | 0.230 |
Why?
|
Papillomaviridae | 2 | 2005 | 153 | 0.230 |
Why?
|
Fluticasone | 5 | 2010 | 30 | 0.230 |
Why?
|
Pharynx | 1 | 2023 | 45 | 0.220 |
Why?
|
Nasal Lavage | 1 | 2022 | 2 | 0.220 |
Why?
|
Neurogenic Inflammation | 1 | 2002 | 2 | 0.220 |
Why?
|
Poaceae | 5 | 2011 | 19 | 0.220 |
Why?
|
Symptom Assessment | 2 | 2020 | 65 | 0.220 |
Why?
|
Dermatitis, Atopic | 1 | 2003 | 52 | 0.220 |
Why?
|
Cilia | 2 | 2016 | 29 | 0.220 |
Why?
|
Serine Endopeptidases | 1 | 2002 | 145 | 0.210 |
Why?
|
Tongue | 2 | 2016 | 57 | 0.210 |
Why?
|
Encephalocele | 1 | 2022 | 24 | 0.210 |
Why?
|
Microbiota | 3 | 2018 | 381 | 0.210 |
Why?
|
Atmosphere Exposure Chambers | 2 | 2001 | 7 | 0.200 |
Why?
|
Young Adult | 7 | 2015 | 5980 | 0.200 |
Why?
|
Speech | 1 | 2021 | 84 | 0.190 |
Why?
|
Bronchial Provocation Tests | 1 | 2000 | 24 | 0.190 |
Why?
|
Research | 1 | 2001 | 253 | 0.180 |
Why?
|
Betacoronavirus | 2 | 2020 | 258 | 0.180 |
Why?
|
Respiratory Tract Infections | 1 | 2021 | 105 | 0.180 |
Why?
|
Lymphangioma | 1 | 1999 | 15 | 0.180 |
Why?
|
Surgery Department, Hospital | 1 | 2020 | 42 | 0.180 |
Why?
|
Combined Modality Therapy | 5 | 2020 | 1686 | 0.180 |
Why?
|
Streptococcal Infections | 2 | 2015 | 57 | 0.180 |
Why?
|
Pregnadienediols | 3 | 2011 | 13 | 0.180 |
Why?
|
Bevacizumab | 1 | 2021 | 281 | 0.180 |
Why?
|
Disease Transmission, Infectious | 1 | 2020 | 57 | 0.180 |
Why?
|
Radiography, Thoracic | 1 | 2001 | 320 | 0.170 |
Why?
|
Pilot Projects | 3 | 2021 | 840 | 0.170 |
Why?
|
Child Development | 1 | 2021 | 163 | 0.170 |
Why?
|
Skin Tests | 3 | 2018 | 44 | 0.170 |
Why?
|
Capillary Permeability | 3 | 2013 | 130 | 0.170 |
Why?
|
Elective Surgical Procedures | 1 | 2020 | 116 | 0.170 |
Why?
|
Operating Rooms | 1 | 2020 | 126 | 0.170 |
Why?
|
Infection Control | 1 | 2020 | 115 | 0.170 |
Why?
|
Goals | 1 | 2019 | 67 | 0.170 |
Why?
|
Dose-Response Relationship, Drug | 10 | 2005 | 1961 | 0.170 |
Why?
|
Antibodies, Blocking | 1 | 2018 | 21 | 0.170 |
Why?
|
Inflammation Mediators | 4 | 2003 | 155 | 0.160 |
Why?
|
Leukocyte Count | 4 | 2012 | 220 | 0.160 |
Why?
|
Pulmonary Ventilation | 2 | 2011 | 32 | 0.160 |
Why?
|
Respiratory Insufficiency | 1 | 2020 | 150 | 0.160 |
Why?
|
Serum Albumin | 5 | 2002 | 130 | 0.160 |
Why?
|
Placebos | 4 | 2008 | 218 | 0.160 |
Why?
|
Mucous Membrane | 4 | 2008 | 83 | 0.160 |
Why?
|
Complementary Therapies | 2 | 2018 | 54 | 0.160 |
Why?
|
Angiogenesis Inhibitors | 1 | 2021 | 311 | 0.160 |
Why?
|
Streptococcus pneumoniae | 5 | 2006 | 48 | 0.160 |
Why?
|
Albumins | 3 | 2008 | 133 | 0.160 |
Why?
|
Biological Therapy | 1 | 2018 | 45 | 0.160 |
Why?
|
Olfactory Mucosa | 2 | 2010 | 33 | 0.160 |
Why?
|
Analysis of Variance | 8 | 2006 | 912 | 0.160 |
Why?
|
Esophagus | 2 | 2009 | 102 | 0.160 |
Why?
|
Dilatation | 1 | 2018 | 48 | 0.160 |
Why?
|
Clemastine | 1 | 1997 | 2 | 0.150 |
Why?
|
Imaging, Three-Dimensional | 3 | 2017 | 579 | 0.150 |
Why?
|
Allergists | 1 | 2016 | 4 | 0.150 |
Why?
|
Pandemics | 2 | 2020 | 740 | 0.150 |
Why?
|
Prognosis | 3 | 2020 | 3680 | 0.150 |
Why?
|
Prostaglandin D2 | 2 | 1996 | 27 | 0.150 |
Why?
|
Immunologic Factors | 1 | 2018 | 170 | 0.150 |
Why?
|
Delphi Technique | 3 | 2023 | 80 | 0.150 |
Why?
|
Cholinergic Antagonists | 2 | 2003 | 26 | 0.150 |
Why?
|
Antibodies, Anti-Idiotypic | 3 | 2013 | 44 | 0.150 |
Why?
|
Medical History Taking | 2 | 2013 | 80 | 0.150 |
Why?
|
CD4 Lymphocyte Count | 1 | 1996 | 66 | 0.140 |
Why?
|
Animals | 14 | 2016 | 26590 | 0.140 |
Why?
|
Anti-Bacterial Agents | 3 | 2014 | 747 | 0.140 |
Why?
|
Leukotriene B4 | 1 | 1996 | 14 | 0.140 |
Why?
|
Inflammation | 7 | 2015 | 923 | 0.140 |
Why?
|
Immunologic Deficiency Syndromes | 1 | 2016 | 47 | 0.140 |
Why?
|
Disease Models, Animal | 5 | 2006 | 2231 | 0.140 |
Why?
|
Immunotherapy | 3 | 2024 | 629 | 0.140 |
Why?
|
Eikenella corrodens | 1 | 2015 | 2 | 0.140 |
Why?
|
Drug Utilization | 1 | 2016 | 65 | 0.140 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 4 | 1998 | 56 | 0.140 |
Why?
|
Trismus | 1 | 2015 | 6 | 0.140 |
Why?
|
Respiratory Hypersensitivity | 2 | 1999 | 41 | 0.140 |
Why?
|
Hypesthesia | 1 | 2015 | 15 | 0.140 |
Why?
|
Leukocytosis | 1 | 2015 | 16 | 0.140 |
Why?
|
Cellulose | 1 | 2016 | 55 | 0.140 |
Why?
|
Gram-Negative Bacterial Infections | 1 | 2015 | 23 | 0.140 |
Why?
|
Tachycardia | 1 | 2015 | 35 | 0.140 |
Why?
|
Muscarinic Antagonists | 1 | 1996 | 55 | 0.130 |
Why?
|
Preoperative Care | 1 | 2018 | 397 | 0.130 |
Why?
|
Patient Care Planning | 1 | 2016 | 81 | 0.130 |
Why?
|
Pharyngeal Diseases | 1 | 2015 | 11 | 0.130 |
Why?
|
Papilloma, Inverted | 1 | 2015 | 6 | 0.130 |
Why?
|
Eustachian Tube | 1 | 2015 | 9 | 0.130 |
Why?
|
Risk Factors | 5 | 2020 | 5420 | 0.130 |
Why?
|
Premedication | 2 | 1994 | 54 | 0.130 |
Why?
|
Respiratory System | 2 | 2011 | 116 | 0.130 |
Why?
|
Administration, Oral | 4 | 2006 | 684 | 0.130 |
Why?
|
Paranasal Sinus Neoplasms | 1 | 2015 | 24 | 0.130 |
Why?
|
Polyps | 1 | 2015 | 28 | 0.130 |
Why?
|
Fever | 1 | 2015 | 125 | 0.130 |
Why?
|
Airway Management | 1 | 2015 | 46 | 0.130 |
Why?
|
Case-Control Studies | 4 | 2020 | 1807 | 0.130 |
Why?
|
Biomarkers | 3 | 2017 | 1718 | 0.130 |
Why?
|
Ancillary Services, Hospital | 1 | 2014 | 1 | 0.130 |
Why?
|
Surgery, Computer-Assisted | 1 | 2016 | 99 | 0.120 |
Why?
|
User-Computer Interface | 1 | 2016 | 185 | 0.120 |
Why?
|
Oxygen | 1 | 2019 | 726 | 0.120 |
Why?
|
Radiography | 2 | 2014 | 813 | 0.120 |
Why?
|
Decision Making | 1 | 2020 | 642 | 0.120 |
Why?
|
Risk Assessment | 2 | 2013 | 2264 | 0.120 |
Why?
|
Phenotype | 3 | 2020 | 2380 | 0.120 |
Why?
|
Body Temperature | 3 | 2005 | 124 | 0.120 |
Why?
|
United States | 7 | 2023 | 6681 | 0.120 |
Why?
|
Rhinometry, Acoustic | 1 | 2014 | 3 | 0.120 |
Why?
|
Autoimmune Diseases | 1 | 2016 | 241 | 0.120 |
Why?
|
Smoking | 2 | 2016 | 609 | 0.120 |
Why?
|
Prednisone | 1 | 2014 | 258 | 0.120 |
Why?
|
Antigens, Fungal | 1 | 2013 | 6 | 0.120 |
Why?
|
Otitis Media | 2 | 2003 | 18 | 0.110 |
Why?
|
Foreign Bodies | 2 | 2009 | 63 | 0.110 |
Why?
|
Anesthetics, Intravenous | 1 | 2013 | 41 | 0.110 |
Why?
|
Injections, Intraocular | 1 | 2013 | 5 | 0.110 |
Why?
|
Olopatadine Hydrochloride | 1 | 2013 | 6 | 0.110 |
Why?
|
Reference Values | 2 | 2013 | 674 | 0.110 |
Why?
|
Drug Resistance | 1 | 2013 | 256 | 0.110 |
Why?
|
Operative Time | 1 | 2013 | 127 | 0.110 |
Why?
|
Lung Neoplasms | 1 | 2005 | 2262 | 0.110 |
Why?
|
Fungi | 1 | 2013 | 65 | 0.110 |
Why?
|
Phleum | 1 | 2012 | 2 | 0.110 |
Why?
|
Immunohistochemistry | 3 | 2011 | 1753 | 0.110 |
Why?
|
Immune System | 1 | 1993 | 93 | 0.110 |
Why?
|
Mites | 1 | 2012 | 16 | 0.110 |
Why?
|
Cost of Illness | 3 | 2015 | 150 | 0.110 |
Why?
|
Anesthetics, Inhalation | 1 | 2013 | 95 | 0.110 |
Why?
|
Cross-Sectional Studies | 3 | 2023 | 1621 | 0.110 |
Why?
|
Antifungal Agents | 1 | 2013 | 117 | 0.110 |
Why?
|
Dust | 1 | 2012 | 26 | 0.110 |
Why?
|
Skin Temperature | 2 | 2003 | 14 | 0.100 |
Why?
|
Bronchi | 3 | 2012 | 229 | 0.100 |
Why?
|
Tumor Necrosis Factors | 1 | 2011 | 14 | 0.100 |
Why?
|
Bodily Secretions | 1 | 2011 | 3 | 0.100 |
Why?
|
Ovalbumin | 3 | 2006 | 109 | 0.100 |
Why?
|
Antigens, Plant | 1 | 2011 | 14 | 0.100 |
Why?
|
Epigenomics | 1 | 2012 | 100 | 0.100 |
Why?
|
Ioxaglic Acid | 1 | 2011 | 7 | 0.100 |
Why?
|
Neck | 2 | 2006 | 100 | 0.100 |
Why?
|
Time Factors | 8 | 2006 | 5214 | 0.100 |
Why?
|
Practice Patterns, Physicians' | 1 | 2016 | 584 | 0.100 |
Why?
|
Airway Resistance | 5 | 1999 | 69 | 0.100 |
Why?
|
Staining and Labeling | 1 | 2011 | 165 | 0.100 |
Why?
|
Ribonucleases | 2 | 2001 | 92 | 0.090 |
Why?
|
Hydroxyapatites | 1 | 2010 | 7 | 0.090 |
Why?
|
T-Lymphocyte Subsets | 1 | 2012 | 272 | 0.090 |
Why?
|
Academic Medical Centers | 1 | 2013 | 380 | 0.090 |
Why?
|
Molar | 1 | 2010 | 21 | 0.090 |
Why?
|
Oral Surgical Procedures | 1 | 2010 | 19 | 0.090 |
Why?
|
Antibodies, Monoclonal, Humanized | 2 | 2013 | 930 | 0.090 |
Why?
|
Colony Count, Microbial | 2 | 2008 | 46 | 0.090 |
Why?
|
Probability | 2 | 2008 | 355 | 0.090 |
Why?
|
Hemostasis, Surgical | 1 | 2010 | 26 | 0.090 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2007 | 1313 | 0.090 |
Why?
|
Arteriovenous Malformations | 1 | 2010 | 41 | 0.090 |
Why?
|
Algorithms | 3 | 2015 | 1830 | 0.090 |
Why?
|
Biopsy | 3 | 1999 | 1163 | 0.090 |
Why?
|
Deafness | 1 | 2009 | 47 | 0.090 |
Why?
|
Cochlear Implantation | 1 | 2009 | 31 | 0.090 |
Why?
|
Neutrophils | 5 | 2001 | 307 | 0.090 |
Why?
|
Transforming Growth Factor beta | 1 | 2011 | 301 | 0.090 |
Why?
|
Matched-Pair Analysis | 1 | 2008 | 43 | 0.080 |
Why?
|
Aged | 10 | 2016 | 18423 | 0.080 |
Why?
|
Age Factors | 1 | 2013 | 1852 | 0.080 |
Why?
|
Flow Cytometry | 4 | 2014 | 679 | 0.080 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2010 | 468 | 0.080 |
Why?
|
Fundoplication | 1 | 2009 | 72 | 0.080 |
Why?
|
Longitudinal Studies | 1 | 2012 | 1019 | 0.080 |
Why?
|
Clinical Trials as Topic | 4 | 2020 | 1169 | 0.080 |
Why?
|
Epidural Abscess | 1 | 2008 | 3 | 0.080 |
Why?
|
Turbinates | 3 | 2015 | 11 | 0.080 |
Why?
|
Phenoxybenzamine | 2 | 2005 | 15 | 0.080 |
Why?
|
Urban Health | 1 | 2008 | 55 | 0.080 |
Why?
|
Eyebrows | 1 | 2008 | 10 | 0.080 |
Why?
|
Disease Progression | 1 | 2013 | 1532 | 0.080 |
Why?
|
Adrenergic alpha-Antagonists | 2 | 2005 | 35 | 0.080 |
Why?
|
Feasibility Studies | 1 | 2010 | 751 | 0.080 |
Why?
|
Foot | 3 | 2003 | 50 | 0.080 |
Why?
|
Lacrimal Apparatus | 1 | 2008 | 11 | 0.080 |
Why?
|
Ciprofloxacin | 1 | 2008 | 29 | 0.080 |
Why?
|
Intermediate Filament Proteins | 1 | 2008 | 35 | 0.080 |
Why?
|
Vocal Cord Paralysis | 1 | 2007 | 26 | 0.080 |
Why?
|
Continuous Positive Airway Pressure | 1 | 2008 | 53 | 0.080 |
Why?
|
Orbit | 1 | 2008 | 37 | 0.080 |
Why?
|
Diagnosis, Differential | 4 | 2018 | 1566 | 0.080 |
Why?
|
Mouth Mucosa | 1 | 2008 | 67 | 0.080 |
Why?
|
Craniotomy | 1 | 2008 | 88 | 0.080 |
Why?
|
Parasympathetic Nervous System | 3 | 2001 | 33 | 0.080 |
Why?
|
Receptors, Histamine H1 | 2 | 2000 | 8 | 0.080 |
Why?
|
Kartagener Syndrome | 1 | 2007 | 1 | 0.070 |
Why?
|
Urban Population | 1 | 2008 | 214 | 0.070 |
Why?
|
Anti-Infective Agents | 1 | 2008 | 90 | 0.070 |
Why?
|
Histamine Antagonists | 2 | 2018 | 12 | 0.070 |
Why?
|
Hypopharynx | 1 | 2006 | 8 | 0.070 |
Why?
|
Specific Pathogen-Free Organisms | 1 | 2006 | 74 | 0.070 |
Why?
|
Videotape Recording | 1 | 2006 | 47 | 0.070 |
Why?
|
Mice | 8 | 2008 | 11356 | 0.070 |
Why?
|
Incidence | 1 | 2011 | 1578 | 0.070 |
Why?
|
Dexamethasone | 1 | 2008 | 326 | 0.070 |
Why?
|
Muscarinic Agonists | 2 | 1996 | 23 | 0.070 |
Why?
|
Disease Management | 2 | 2020 | 327 | 0.070 |
Why?
|
Fluoroscopy | 1 | 2006 | 119 | 0.070 |
Why?
|
Saline Solution, Hypertonic | 1 | 2006 | 24 | 0.070 |
Why?
|
Water | 2 | 2005 | 277 | 0.070 |
Why?
|
Sensation | 1 | 2006 | 45 | 0.070 |
Why?
|
Nasal Surgical Procedures | 2 | 2016 | 8 | 0.070 |
Why?
|
E-Selectin | 2 | 1996 | 30 | 0.070 |
Why?
|
Sodium Chloride | 1 | 2006 | 88 | 0.070 |
Why?
|
Plant Extracts | 1 | 2008 | 244 | 0.070 |
Why?
|
Head | 1 | 2006 | 132 | 0.070 |
Why?
|
Prevalence | 3 | 2020 | 1239 | 0.070 |
Why?
|
Cystic Fibrosis | 3 | 1995 | 112 | 0.070 |
Why?
|
Follow-Up Studies | 3 | 2009 | 3642 | 0.060 |
Why?
|
Physical Examination | 2 | 2018 | 149 | 0.060 |
Why?
|
Single-Blind Method | 2 | 2021 | 153 | 0.060 |
Why?
|
Healthcare Disparities | 1 | 2009 | 372 | 0.060 |
Why?
|
Deglutition Disorders | 1 | 2006 | 115 | 0.060 |
Why?
|
Predictive Value of Tests | 2 | 2019 | 1673 | 0.060 |
Why?
|
Referral and Consultation | 2 | 2020 | 328 | 0.060 |
Why?
|
Mometasone Furoate | 3 | 2011 | 18 | 0.060 |
Why?
|
Fatal Outcome | 1 | 2005 | 295 | 0.060 |
Why?
|
Therapeutic Irrigation | 2 | 2002 | 60 | 0.060 |
Why?
|
Cost-Benefit Analysis | 2 | 2018 | 455 | 0.060 |
Why?
|
Antibodies, Monoclonal | 1 | 2010 | 1376 | 0.060 |
Why?
|
Gene Expression Regulation | 2 | 2014 | 1921 | 0.060 |
Why?
|
Basophils | 2 | 1994 | 25 | 0.060 |
Why?
|
Suppuration | 1 | 2003 | 9 | 0.060 |
Why?
|
Cephalexin | 1 | 2003 | 6 | 0.060 |
Why?
|
Bronchoscopy | 1 | 2005 | 152 | 0.060 |
Why?
|
Kinetics | 2 | 1999 | 1513 | 0.060 |
Why?
|
Vasoconstrictor Agents | 1 | 2004 | 54 | 0.060 |
Why?
|
Administration, Topical | 2 | 2008 | 95 | 0.060 |
Why?
|
Tryptases | 1 | 2002 | 12 | 0.060 |
Why?
|
Cell Separation | 2 | 2014 | 196 | 0.060 |
Why?
|
Pruritus | 1 | 2002 | 26 | 0.060 |
Why?
|
Epithelial Cells | 2 | 2012 | 669 | 0.060 |
Why?
|
Community-Acquired Infections | 1 | 2003 | 63 | 0.060 |
Why?
|
Cultural Diversity | 1 | 2023 | 51 | 0.060 |
Why?
|
Demography | 1 | 2023 | 177 | 0.060 |
Why?
|
Databases, Factual | 1 | 2006 | 816 | 0.050 |
Why?
|
Brain | 1 | 2013 | 2216 | 0.050 |
Why?
|
Injections, Subcutaneous | 1 | 2022 | 117 | 0.050 |
Why?
|
Climate Change | 1 | 2023 | 42 | 0.050 |
Why?
|
T-Lymphocytes | 2 | 2002 | 1195 | 0.050 |
Why?
|
Patient Satisfaction | 1 | 2006 | 455 | 0.050 |
Why?
|
Schools, Medical | 1 | 2023 | 123 | 0.050 |
Why?
|
Neurosurgery | 1 | 2023 | 84 | 0.050 |
Why?
|
Aged, 80 and over | 3 | 2016 | 6513 | 0.050 |
Why?
|
Molecular Structure | 1 | 2002 | 287 | 0.050 |
Why?
|
Supine Position | 1 | 2001 | 30 | 0.050 |
Why?
|
Structure-Activity Relationship | 1 | 2002 | 408 | 0.050 |
Why?
|
Socioeconomic Factors | 2 | 2018 | 567 | 0.050 |
Why?
|
Mice, Knockout | 1 | 2006 | 1924 | 0.050 |
Why?
|
Neuropeptides | 2 | 1999 | 112 | 0.050 |
Why?
|
Skull Base | 1 | 2022 | 47 | 0.050 |
Why?
|
Lidocaine | 3 | 2003 | 63 | 0.050 |
Why?
|
Respiratory Mucosa | 2 | 2018 | 88 | 0.050 |
Why?
|
Research Support as Topic | 1 | 2001 | 80 | 0.050 |
Why?
|
Receptors, Chemokine | 1 | 2001 | 31 | 0.050 |
Why?
|
Chemokines, CC | 1 | 2001 | 34 | 0.050 |
Why?
|
Receptors, Muscarinic | 1 | 2001 | 49 | 0.050 |
Why?
|
Antibody Specificity | 2 | 1997 | 129 | 0.050 |
Why?
|
Hearing | 1 | 2021 | 59 | 0.050 |
Why?
|
General Surgery | 1 | 2023 | 229 | 0.050 |
Why?
|
Internationality | 1 | 2021 | 69 | 0.050 |
Why?
|
Body Temperature Regulation | 1 | 2000 | 56 | 0.050 |
Why?
|
Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2000 | 17 | 0.050 |
Why?
|
Atrophy | 1 | 2001 | 117 | 0.050 |
Why?
|
Educational Status | 1 | 2021 | 190 | 0.050 |
Why?
|
Workload | 1 | 2001 | 128 | 0.050 |
Why?
|
Reaction Time | 1 | 2001 | 309 | 0.050 |
Why?
|
National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2020 | 4 | 0.050 |
Why?
|
Bronchodilator Agents | 1 | 2000 | 65 | 0.050 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 30 | 0.050 |
Why?
|
Personal Protective Equipment | 1 | 2020 | 32 | 0.050 |
Why?
|
Masks | 1 | 2000 | 29 | 0.050 |
Why?
|
Reproducibility of Results | 3 | 2019 | 2706 | 0.050 |
Why?
|
Observational Studies as Topic | 1 | 2020 | 48 | 0.040 |
Why?
|
Nose Neoplasms | 1 | 1999 | 31 | 0.040 |
Why?
|
Checklist | 1 | 2020 | 57 | 0.040 |
Why?
|
Antibody Formation | 3 | 1997 | 171 | 0.040 |
Why?
|
Disease Susceptibility | 1 | 2020 | 193 | 0.040 |
Why?
|
Faculty, Medical | 1 | 2001 | 179 | 0.040 |
Why?
|
Sensitivity and Specificity | 2 | 2019 | 1992 | 0.040 |
Why?
|
Capsaicin | 2 | 1999 | 44 | 0.040 |
Why?
|
Cross Infection | 1 | 2020 | 141 | 0.040 |
Why?
|
Leukocytes | 2 | 2001 | 202 | 0.040 |
Why?
|
Benzimidazoles | 1 | 2000 | 140 | 0.040 |
Why?
|
Parents | 1 | 2021 | 272 | 0.040 |
Why?
|
Receptors, Interleukin-2 | 1 | 1998 | 66 | 0.040 |
Why?
|
Chemotaxis, Leukocyte | 1 | 1998 | 38 | 0.040 |
Why?
|
Epidemiologic Methods | 1 | 2018 | 59 | 0.040 |
Why?
|
Immunization | 1 | 1998 | 158 | 0.040 |
Why?
|
Occupational Diseases | 1 | 2018 | 55 | 0.040 |
Why?
|
Respiration, Artificial | 1 | 2020 | 334 | 0.040 |
Why?
|
ROC Curve | 1 | 2019 | 752 | 0.040 |
Why?
|
Recurrence | 2 | 2018 | 1139 | 0.040 |
Why?
|
Tachyphylaxis | 2 | 1994 | 14 | 0.040 |
Why?
|
Peroxidases | 1 | 1997 | 34 | 0.040 |
Why?
|
Patient Participation | 1 | 2019 | 216 | 0.040 |
Why?
|
Bias | 1 | 2017 | 127 | 0.040 |
Why?
|
Respiratory Therapy | 1 | 1997 | 14 | 0.040 |
Why?
|
CD4-CD8 Ratio | 1 | 1996 | 18 | 0.040 |
Why?
|
Epithelium | 1 | 1998 | 319 | 0.040 |
Why?
|
Allergy and Immunology | 1 | 2016 | 12 | 0.040 |
Why?
|
Otolaryngologists | 1 | 2016 | 4 | 0.040 |
Why?
|
Respiration | 2 | 2000 | 262 | 0.040 |
Why?
|
Chemokine CCL5 | 1 | 1996 | 16 | 0.040 |
Why?
|
Albuterol | 1 | 1997 | 35 | 0.040 |
Why?
|
Th2 Cells | 2 | 2012 | 146 | 0.040 |
Why?
|
Probiotics | 1 | 2018 | 81 | 0.040 |
Why?
|
Mice, Inbred BALB C | 3 | 2006 | 1047 | 0.040 |
Why?
|
Adrenergic beta-Agonists | 1 | 1997 | 72 | 0.040 |
Why?
|
Nasal Sprays | 1 | 2016 | 9 | 0.040 |
Why?
|
Lymphocyte Count | 1 | 1996 | 94 | 0.040 |
Why?
|
Administration, Inhalation | 1 | 1997 | 188 | 0.040 |
Why?
|
Prostaglandins | 1 | 1996 | 43 | 0.040 |
Why?
|
Attitude of Health Personnel | 1 | 2001 | 636 | 0.040 |
Why?
|
Mandibular Advancement | 1 | 2016 | 6 | 0.030 |
Why?
|
Oropharynx | 1 | 2016 | 15 | 0.030 |
Why?
|
Sphenoid Sinus | 1 | 1995 | 6 | 0.030 |
Why?
|
Internal Fixators | 1 | 2016 | 14 | 0.030 |
Why?
|
Quality Assurance, Health Care | 1 | 2017 | 220 | 0.030 |
Why?
|
Risk | 1 | 2017 | 674 | 0.030 |
Why?
|
Anatomic Landmarks | 1 | 2016 | 31 | 0.030 |
Why?
|
Models, Anatomic | 1 | 2016 | 91 | 0.030 |
Why?
|
Environmental Exposure | 1 | 2018 | 296 | 0.030 |
Why?
|
Peptide Hydrolases | 2 | 1992 | 100 | 0.030 |
Why?
|
Nebulizers and Vaporizers | 2 | 1994 | 55 | 0.030 |
Why?
|
Acupuncture Therapy | 1 | 2015 | 11 | 0.030 |
Why?
|
Trachea | 1 | 1996 | 293 | 0.030 |
Why?
|
Intubation, Intratracheal | 1 | 1996 | 144 | 0.030 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 1994 | 71 | 0.030 |
Why?
|
Physician's Role | 1 | 2016 | 179 | 0.030 |
Why?
|
Models, Biological | 2 | 2008 | 1749 | 0.030 |
Why?
|
Mucocele | 1 | 1994 | 4 | 0.030 |
Why?
|
Natural Orifice Endoscopic Surgery | 1 | 2015 | 38 | 0.030 |
Why?
|
Maxillary Sinus Neoplasms | 1 | 1994 | 8 | 0.030 |
Why?
|
Forecasting | 1 | 2016 | 305 | 0.030 |
Why?
|
Infant, Newborn, Diseases | 1 | 2015 | 111 | 0.030 |
Why?
|
Face | 1 | 1995 | 114 | 0.030 |
Why?
|
Interleukin-4 | 1 | 1994 | 127 | 0.030 |
Why?
|
Cell Movement | 1 | 1998 | 758 | 0.030 |
Why?
|
GATA3 Transcription Factor | 1 | 2014 | 48 | 0.030 |
Why?
|
Mucus | 1 | 1994 | 19 | 0.030 |
Why?
|
Interdisciplinary Communication | 1 | 2015 | 130 | 0.030 |
Why?
|
Triamcinolone Acetonide | 1 | 1993 | 8 | 0.030 |
Why?
|
Virus Diseases | 1 | 2014 | 97 | 0.030 |
Why?
|
Platelet Activating Factor | 1 | 1994 | 53 | 0.030 |
Why?
|
Phytotherapy | 1 | 2015 | 133 | 0.030 |
Why?
|
Patient Care | 2 | 2004 | 100 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2017 | 865 | 0.030 |
Why?
|
Guidelines as Topic | 2 | 2004 | 162 | 0.030 |
Why?
|
Cold Temperature | 1 | 1993 | 157 | 0.030 |
Why?
|
Diphenhydramine | 1 | 1993 | 17 | 0.030 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 246 | 0.030 |
Why?
|
Stress, Physiological | 1 | 1995 | 227 | 0.030 |
Why?
|
Receptors, Cholinergic | 1 | 1993 | 76 | 0.030 |
Why?
|
Paper | 1 | 1992 | 10 | 0.030 |
Why?
|
Forkhead Transcription Factors | 1 | 2014 | 166 | 0.030 |
Why?
|
Filtration | 1 | 1992 | 25 | 0.030 |
Why?
|
Linear Models | 1 | 1994 | 422 | 0.030 |
Why?
|
Societies, Medical | 1 | 2016 | 573 | 0.030 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 1996 | 558 | 0.030 |
Why?
|
Blood Circulation | 1 | 2012 | 29 | 0.030 |
Why?
|
Administration, Sublingual | 1 | 2012 | 5 | 0.030 |
Why?
|
Drug Evaluation | 1 | 1992 | 141 | 0.030 |
Why?
|
Immersion | 2 | 2003 | 21 | 0.030 |
Why?
|
Pediatrics | 1 | 2016 | 344 | 0.030 |
Why?
|
Interleukin-1 | 1 | 2012 | 71 | 0.030 |
Why?
|
Mice, Inbred C57BL | 3 | 2008 | 3095 | 0.030 |
Why?
|
Up-Regulation | 1 | 1994 | 715 | 0.030 |
Why?
|
Hypersensitivity, Immediate | 1 | 1992 | 62 | 0.030 |
Why?
|
Research Design | 1 | 2015 | 594 | 0.020 |
Why?
|
Leukotrienes | 1 | 1991 | 20 | 0.020 |
Why?
|
Eosinophil Granule Proteins | 2 | 2001 | 20 | 0.020 |
Why?
|
Europe | 1 | 2012 | 309 | 0.020 |
Why?
|
Computer Simulation | 1 | 2016 | 1078 | 0.020 |
Why?
|
Health Services Needs and Demand | 1 | 2012 | 102 | 0.020 |
Why?
|
Omalizumab | 1 | 2010 | 8 | 0.020 |
Why?
|
Trees | 1 | 2011 | 30 | 0.020 |
Why?
|
Agnosia | 1 | 2010 | 5 | 0.020 |
Why?
|
Antigens, CD | 1 | 2012 | 458 | 0.020 |
Why?
|
Injections, Intralesional | 1 | 2010 | 22 | 0.020 |
Why?
|
Alveolar Bone Loss | 1 | 2010 | 20 | 0.020 |
Why?
|
Blood Proteins | 2 | 2001 | 144 | 0.020 |
Why?
|
Bacteria | 1 | 2014 | 447 | 0.020 |
Why?
|
Hydroxyzine | 1 | 1989 | 7 | 0.020 |
Why?
|
Receptors, Adrenergic, alpha | 1 | 1989 | 16 | 0.020 |
Why?
|
Cetirizine | 1 | 1989 | 12 | 0.020 |
Why?
|
Health Status Indicators | 1 | 2010 | 105 | 0.020 |
Why?
|
Audiology | 1 | 2009 | 2 | 0.020 |
Why?
|
Angiography, Digital Subtraction | 1 | 2010 | 92 | 0.020 |
Why?
|
Language Development Disorders | 1 | 2009 | 24 | 0.020 |
Why?
|
Benzhydryl Compounds | 1 | 1989 | 48 | 0.020 |
Why?
|
Education | 1 | 2009 | 58 | 0.020 |
Why?
|
Self Efficacy | 1 | 2009 | 53 | 0.020 |
Why?
|
Recovery of Function | 1 | 2010 | 272 | 0.020 |
Why?
|
Esophagoscopy | 1 | 2009 | 87 | 0.020 |
Why?
|
Calcium Channels | 1 | 1989 | 182 | 0.020 |
Why?
|
Serotonin | 1 | 1989 | 218 | 0.020 |
Why?
|
Cranial Fossa, Anterior | 1 | 2008 | 4 | 0.020 |
Why?
|
Pneumocephalus | 1 | 2008 | 10 | 0.020 |
Why?
|
Frontal Sinus | 1 | 2008 | 7 | 0.020 |
Why?
|
Data Collection | 1 | 2009 | 372 | 0.020 |
Why?
|
Patient Compliance | 1 | 2009 | 228 | 0.020 |
Why?
|
Dopamine | 1 | 1989 | 275 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2011 | 1001 | 0.020 |
Why?
|
Esophagitis | 1 | 2008 | 43 | 0.020 |
Why?
|
Tissue and Organ Harvesting | 1 | 2008 | 78 | 0.020 |
Why?
|
Random Allocation | 2 | 2001 | 332 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2012 | 2819 | 0.020 |
Why?
|
Drainage | 1 | 2008 | 157 | 0.020 |
Why?
|
Lactoferrin | 2 | 1997 | 11 | 0.020 |
Why?
|
Health Services Accessibility | 1 | 2009 | 394 | 0.020 |
Why?
|
Placebo Effect | 1 | 2005 | 31 | 0.020 |
Why?
|
Pain Measurement | 1 | 2006 | 321 | 0.020 |
Why?
|
Skin | 1 | 2008 | 554 | 0.020 |
Why?
|
Respiratory Mechanics | 1 | 2005 | 102 | 0.020 |
Why?
|
Pain, Postoperative | 1 | 2006 | 240 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2005 | 916 | 0.010 |
Why?
|
Observer Variation | 1 | 2004 | 603 | 0.010 |
Why?
|
Regional Blood Flow | 1 | 2003 | 197 | 0.010 |
Why?
|
Sympathetic Nervous System | 1 | 2003 | 104 | 0.010 |
Why?
|
Anesthetics, Local | 1 | 2003 | 76 | 0.010 |
Why?
|
Receptors, CCR3 | 1 | 2001 | 1 | 0.010 |
Why?
|
Chemokine CCL11 | 1 | 2001 | 11 | 0.010 |
Why?
|
Air Conditioning | 1 | 2001 | 6 | 0.010 |
Why?
|
Receptor, Muscarinic M2 | 1 | 2001 | 11 | 0.010 |
Why?
|
Intracellular Fluid | 1 | 2001 | 34 | 0.010 |
Why?
|
Binding, Competitive | 1 | 2001 | 145 | 0.010 |
Why?
|
Acoustics | 1 | 2001 | 51 | 0.010 |
Why?
|
Th1 Cells | 1 | 2001 | 164 | 0.010 |
Why?
|
Calcium Signaling | 1 | 2001 | 129 | 0.010 |
Why?
|
Neurokinin A | 1 | 1999 | 12 | 0.010 |
Why?
|
Calcitonin Gene-Related Peptide | 1 | 1999 | 38 | 0.010 |
Why?
|
Substance P | 1 | 1999 | 61 | 0.010 |
Why?
|
Nasopharynx | 1 | 1999 | 47 | 0.010 |
Why?
|
Hospitalization | 1 | 2004 | 851 | 0.010 |
Why?
|
Eosinophil Peroxidase | 1 | 1997 | 14 | 0.010 |
Why?
|
N-Formylmethionine Leucyl-Phenylalanine | 1 | 1997 | 39 | 0.010 |
Why?
|
Stereoisomerism | 1 | 1997 | 102 | 0.010 |
Why?
|
Anti-Asthmatic Agents | 1 | 1997 | 76 | 0.010 |
Why?
|
Histocytochemistry | 1 | 1996 | 130 | 0.010 |
Why?
|
Mutation | 1 | 2008 | 3968 | 0.010 |
Why?
|
Cell Line | 1 | 2001 | 2469 | 0.010 |
Why?
|
Calcium | 1 | 2001 | 1156 | 0.010 |
Why?
|
Intensive Care Units, Pediatric | 1 | 1996 | 99 | 0.010 |
Why?
|
Jaw Neoplasms | 1 | 1995 | 5 | 0.010 |
Why?
|
Facial Neoplasms | 1 | 1995 | 25 | 0.010 |
Why?
|
Cytodiagnosis | 1 | 1995 | 42 | 0.010 |
Why?
|
Tears | 1 | 1994 | 7 | 0.010 |
Why?
|
Soft Tissue Infections | 1 | 1995 | 26 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2001 | 1981 | 0.010 |
Why?
|
Biopsy, Needle | 1 | 1995 | 235 | 0.010 |
Why?
|
Anesthesia | 1 | 1996 | 164 | 0.010 |
Why?
|
Tosylarginine Methyl Ester | 1 | 1994 | 5 | 0.010 |
Why?
|
Gas Chromatography-Mass Spectrometry | 1 | 1994 | 40 | 0.010 |
Why?
|
Acute-Phase Reaction | 1 | 1994 | 16 | 0.010 |
Why?
|
Phospholipases A | 1 | 1994 | 45 | 0.010 |
Why?
|
Radioallergosorbent Test | 1 | 1993 | 8 | 0.010 |
Why?
|
Frontal Sinusitis | 1 | 1993 | 2 | 0.010 |
Why?
|
Sphenoid Sinusitis | 1 | 1993 | 2 | 0.010 |
Why?
|
Ethmoid Sinusitis | 1 | 1993 | 4 | 0.010 |
Why?
|
Anesthesia, Local | 1 | 1993 | 27 | 0.010 |
Why?
|
Cephalometry | 1 | 1993 | 50 | 0.010 |
Why?
|
Tuberculosis | 1 | 1995 | 110 | 0.010 |
Why?
|
Nasal Septum | 1 | 1993 | 28 | 0.010 |
Why?
|
Seasons | 1 | 1993 | 223 | 0.010 |
Why?
|
Kinins | 1 | 1992 | 31 | 0.010 |
Why?
|
Proteins | 1 | 1994 | 777 | 0.010 |
Why?
|